Publication Cover
Expert Review of Precision Medicine and Drug Development
Personalized medicine in drug development and clinical practice
Volume 2, 2017 - Issue 5
67
Views
1
CrossRef citations to date
0
Altmetric
Review

Prospects for precision therapy of bladder urothelial carcinoma

, , , , , , , & show all
Pages 261-274 | Received 02 Jun 2017, Accepted 04 Oct 2017, Published online: 25 Oct 2017
 

ABSTRACT

Introduction: In cancer, precision medicine, frequently referred to as precision oncology, implies the use of specific information about a person’s tumor to assist diagnosis, guide treatment, find out how well treatment is working, or if it is relevant to patient’s prognosis.

Area covered: Molecular classification of bladder cancer as the bases for cancer therapy, immunotherapy and algorithms on how to use the different drugs in these patients, and other emerging target related therapies from relevant clinical trials.

Expert commentary: Standard therapy relies on chemotherapy, but results associated with chemotherapy are poor. Recently introduced checkpoint inhibitors, anti-PD1 and anti-PDL1 antibodies, represent a major advance for treating advanced/metastatic bladder urothelial carcinoma. Nevertheless, results are far from perfect with many patients gaining no advantage with the use of these agents. In previously treated and in cisplatin ineligible patients, these agents outperformed standard chemotherapy in terms of overall survival

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This paper was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.